US Corporate Distress Financial Stress SEC Filings — April 27, 2026

27-04-2026

Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire all outstanding shares of Organon & Co. for $14.00 per share in cash, implying an enterprise value of $11.75 billion. The transaction positions the combined entity among the top 25 global pharmaceutical companies with $12.4 billion in revenue, strengthens Sun Pharma's women's health and biosimilars portfolios, and is expected to nearly double EBITDA and cash flow, though post-transaction Net Debt/EBITDA stands at 2.3x. The deal awaits regulatory approvals and Organon stockholder approval, with closure anticipated in early 2027 amid risks such as potential delays, competing bids, or failure to consummate.

• ·Transaction to be funded by Sun Pharma's cash resources and bank financing.
• ·Organon portfolio includes over 70 products commercialized in 140 countries.
• ·Combined company presence in 150 countries, with 18 large markets each over $100M revenue.
• ·Advisors: J.P. Morgan and Jefferies (Sun Pharma financial), Morgan Stanley and Goldman Sachs (Organon financial).

27-04-2026

On April 22, 2026, GAMCO Natural Resources, Gold & Income Trust (NYSE: GNT) entered into a Sales Agreement with G.research, LLC to offer and sell up to 1,000,000 common shares of beneficial interest at-the-market, with a minimum price not less than the current net asset value per share plus commission. The offering commenced on April 24, 2026, pursuant to a prospectus supplement dated April 24, 2026, and an accompanying prospectus dated February 5, 2024, under effective shelf registration statement Form N-2 (File No. 333-276020). No shares have been sold yet, and the agreement enables flexible capital raising without specified financial impact.

• ·Common shares par value $0.001 per share
• ·Securities registered on New York Stock Exchange under symbols GNT and GNT Pr A
• ·Registration Statement File No. 333-276020

27-04-2026

Driven Brands Holdings Inc.'s indirect wholly-owned subsidiaries, Driven Holdings Parent LLC and Driven Holdings, LLC, entered into a Fourth Amendment and limited waiver to their revolving credit facility under the Credit Agreement on April 24, 2026. The amendment waives any potential defaults from the intent to restate financial statements for fiscal years ending December 30, 2023, December 28, 2024, and the first three quarters of the fiscal year ending December 27, 2025, while extending the delivery deadline for FY2025 financials to June 10, 2026, and Q1 2026 financials to 45 days thereafter. This signals ongoing financial reporting challenges with no positive operational metrics disclosed.

• ·Fiscal quarters to restate: first three quarters of fiscal year ending December 27, 2025.
• ·Q1 2026 fiscal quarter ends March 28, 2026.
• ·Credit Agreement originally dated May 27, 2021.

27-04-2026

SiteOne Landscape Supply, through its subsidiaries SiteOne Landscape Supply Holding, LLC and SiteOne Landscape Supply, LLC, entered into the First Amendment to the Amended and Restated Credit Agreement dated July 22, 2022, on April 22, 2026. The amendment facilitates the exit of certain Exiting Lenders, entry of New Lenders, reallocation of commitments among Existing and New Lenders, and prepayment of existing loans with new revolving credit loans upon the First Amendment Effective Date. No specific changes to commitment amounts or financial terms are detailed in the filing, with schedules amended but not quantified here.

• ·Original Credit Agreement dated July 22, 2022
• ·Fee Letter dated March 9, 2026
• ·Effectiveness subject to execution by Lenders representing 100% of Commitments, guarantor consents, certificates, representations and warranties, no Default, legal opinion, and payment of fees/expenses

27-04-2026

Oppenheimer Holdings Inc. (OPY) agreed to a $70 million settlement of the 'Cash Sweep' class action litigation filed in June 2025, avoiding a jury trial where plaintiffs sought over $440 million in damages based on discovery assertions. The settlement, subject to District Court approval within up to 90 days and formal documentation within 60 days, provides a full release of claims without admission of liability and is fully tax-deductible, but will significantly impact Q1 2026 earnings despite competitive rates during the disputed period from 2022. Class certification was granted on December 8, 2025, with trial set for June 2026.

• ·Litigation: Liberty Capital Group v. Oppenheimer Holdings Inc., et al., No. 1:25-cv04822-JSR, U.S. District Court Southern District of New York
• ·Company headquartered in New York with institutional businesses in London, Tel Aviv, and Hong Kong
• ·Earnings release expected May 1, 2026; Form 10-Q for quarter ended March 31, 2026 filed around same time

27-04-2026

Auddia Inc. commenced a public offering on April 24, 2026, issuing 1,405,006 shares of common stock, pre-funded warrants to purchase 3,679,737 shares, and common warrants to purchase 5,084,743 shares at $2.36 per unit (or $2.359 per pre-funded unit), expected to generate approximately $12 million in gross proceeds and $10.9 million in net proceeds after fees. The net proceeds will fund working capital and general corporate purposes, with Dawson James Securities, Inc. as placement agent receiving a 7.0% cash fee and a 90-day lock-up on new share issuances imposed. Common warrants expire upon the pending merger with McCarthy Finney, Inc. (announced February 17, 2026) or five years from exercise.

• ·Pre-funded warrants immediately exercisable with $0.001 exercise price.
• ·Common warrants immediately exercisable at $2.36, adjustable downward by board, expire on merger closing or 5 years from initial exercise.
• ·Ownership limits prevent beneficial ownership exceeding 4.99% or 9.99% post-exercise.
• ·Offering pursuant to S-1 Registration Statement (No. 333-294887) effective April 23, 2026.

27-04-2026

Fulcrum Therapeutics reported positive Phase 1b PIONEER trial data for pociredir showing robust HbF induction, hemolysis/anemia improvements, and VOC reduction trends, with plans to initiate a potential registration-enabling trial in H2 2026 and cash of $333.3M supporting runway into 2029. However, Q1 2026 net loss widened 7% YoY to $18.9M, driven by R&D expenses up 5% to $14.1M and G&A up 16% to $8.1M, while cash decreased $19.0M QoQ to $333.3M. The company appointed Josh Lehrer to its Board and announced CFO Alan Musso's retirement later in 2026.

• ·Dosed first patient in open-label long-term dosing trial for pociredir.
• ·PIONEER trial abstract accepted for oral presentation at Foundation for Sickle Cell Disease Research Symposium in June 2026.
• ·Working capital of $328.8M as of March 31, 2026, down from $344.4M as of December 31, 2025.
• ·Pociredir granted Fast Track and Orphan Drug Designation from FDA for SCD.

27-04-2026

U.S. Energy Corp. (NASDAQ: USEG) executed a five-year, 100% take-or-pay helium offtake agreement with an unnamed investment-grade global industrial gas company for up to 1.2 MMCF per month (14.4 MMCF annually) from its Big Sky Carbon Hub at a fixed $285/MCF plant-gate price, with annual CPI-linked escalation starting March 1, 2028. The deal fully contracts Phase 1 helium volumes, supporting commercial operations targeted for Q1 2027 and de-risking the project alongside a recently expanded senior secured credit facility. No declines or flat metrics reported; the agreement positions helium as the initial contracted revenue stream in a multi-revenue platform including carbon management.

• ·Five-year initial term with year-three price redetermination option
• ·Phase 1 commercial operations targeted for Q1 2027; Phase 2 expected 2029 with 2-3x processing capacity
• ·Counterparty assumes all transportation, processing, and downstream costs
• ·EPA MRV plan approvals anticipated summer 2026
• ·Expanded senior secured credit facility closed April 20, 2026

27-04-2026

Solstice Advanced Materials Inc. announced a quarterly dividend of $0.075 per share on April 27, 2026, payable on June 10, 2026, to shareholders of record as of the close of business on May 27, 2026. The press release detailing the dividend is filed as Exhibit 99.1.

• ·Filing date: April 27, 2026; Date of earliest event: April 24, 2026
• ·Common stock: par value $0.01 per share, trading symbol SOLS on Nasdaq
• ·Principal executive offices: 115 Tabor Road, Morris Plains, New Jersey 07950

27-04-2026

Greenlane Holdings, Inc. regained compliance with Nasdaq Listing Rule 5550(a)(2) minimum bid price requirement on April 21, 2026, leading to the cancellation of its delisting hearing scheduled for May 5, 2026, and continued trading of its Class A Common Stock (GNLN) on the Nasdaq Capital Market. Certain warrant holders affiliated with the board entered into Lock-Up Agreements on April 21, 2026, covering Warrants to purchase 162,760 shares of Common Stock, restricting sales until April 23, 2027. This resolves the delisting risk initially notified on March 25, 2026.

• ·Nasdaq notice received on March 25, 2026, for failure to maintain $1.00 minimum bid price for 30 consecutive business days.
• ·Strategic Advisory Agreement with Advisors dated October 23, 2025, issued Warrants with initial exercise date of April 23, 2026.
• ·Press releases issued on April 21, 2026 (Exhibit 99.1) and April 27, 2026 (Exhibit 99.2).

27-04-2026

Morgan Stanley Direct Lending Fund entered into the First Amendment to its Amended and Restated Senior Secured Revolving Credit Agreement, originally dated February 25, 2025, effective April 23, 2026, with Truist Bank as Administrative Agent and multiple lenders party thereto. The amended facility provides commitments totaling $1,450,000,000. Subsidiary guarantors DLF SPV LLC, DLF CA SPV LLC, and DLF Equity Holdings LLC reaffirmed their guarantees and security interests, with representations confirming no Defaults or Events of Default.

• ·Amendment amends the Credit Agreement by deleting stricken text and adding double-underlined text as per Exhibit A, and restates Schedules in Exhibit B.
• ·Conditions precedent include signed counterparts, legal opinion from Dechert LLP, organizational documents, and payment of invoiced fees.
• ·Governed by New York law; no waiver of existing rights.

27-04-2026

Riot Platforms, Inc. entered into a Second Amended and Restated Credit Agreement dated as of April 21, 2026, with Coinbase Credit, Inc. as Lender, Collateral Agent, and Administrative Agent, providing for a U.S.$200,000,000 credit facility collateralized by Bitcoin. This amends and restates the prior Existing Credit Agreement originally dated April 22, 2025. The agreement includes terms for borrowings, collateral adjustments based on LTV ratios, and events of default.

• ·Collateral Account: account number [***] with Coinbase Custody Trust Company, LLC.
• ·Availability Period: from Original Signing Date to three months after.
• ·Prior agreements: Original Credit Agreement (April 22, 2025), Existing Credit Agreement (First Amendment and Restatement Effective Date).

27-04-2026

On April 20, 2026, Brookfield Oaktree Holdings, LLC (BOH) entered into a Distribution Agreement with affiliate Brookfield Oaktree Holdings Canada Inc. (BOHCI), distributing 100 Common Shares of OCG NTR Holdings LLC (NTR), representing 100% of BOH's equity interests in NTR, via an in-kind distribution in respect of BOH's Class A common units. NTR indirectly holds 100% interests in entities including Brookfield Real Estate Income Trust Inc. The transaction was completed on the same date.

• ·Filing date: April 27, 2026
• ·BOHCI is an affiliate of Brookfield Corporation, sole holder of BOH’s Class A common units
• ·Distribution Agreement attached as Exhibit 10.1

27-04-2026

Martin Marietta Materials, Inc. (NYSE: MLM) announced the appointment of Christopher W. Samborski as Executive Vice President and Chief Operating Officer, effective May 1, 2026, following his successful leadership of the West and Specialties Divisions. Samborski, who joined the company in 2018 after roles at Caterpillar Inc. and Johnson & Johnson, was praised by Chair and CEO Ward Nye for his impact on operations and culture. Kirk Light has assumed leadership of the West and Specialties Divisions while retaining his Southwest Division role, amid the company's record 2025 results.

• ·Mr. Samborski's prior roles at Martin Marietta: President of Specialties Division (2022-2025), Vice President of Strategic Finance, Procurement and Supply Chain (2020-2021), Vice President of Strategic Finance (2018-2020).
• ·Martin Marietta operates in 28 states, Canada, and The Bahamas.

27-04-2026

Bentley Systems, Incorporated entered into a First Amendment and Incremental Facility Agreement dated April 23, 2026, establishing new First Incremental Term Commitments for up to $550,000,000 in Incremental Term Loans under its existing credit agreement originally dated October 18, 2024. The amendment was agreed upon by the Borrower, Subsidiary Loan Parties, PNC Bank as Administrative Agent, and First Incremental Term Lenders, with the loans to be repaid per the amended terms and maturing on the First Incremental Term Loan Maturity Date. Representations confirm no Defaults or Events of Default exist before or after the amendment, with pro forma compliance to covenants including a Net Senior Secured Leverage Ratio not exceeding the maximum permitted minus 0.25.

• ·Effective upon satisfaction of conditions including executed agreements, delivery of First Incremental Term Notes, officer certificates, legal opinion from Faegre Drinker Biddle & Reath LLP, lien searches, fees, insurance evidence, KYC documentation, and Borrowing Request.
• ·Pro forma as of December 31, 2025: compliance with Sections 6.12 and 6.13 covenants; Net Senior Secured Leverage Ratio ≤ Maximum Permitted Net Senior Secured Leverage Ratio minus 0.25.
• ·First Incremental Term Commitments terminate upon funding on First Amendment Effective Date.

27-04-2026

Chicago Mercantile Exchange Inc., a subsidiary of CME Group Inc., entered into Amendment No. 11 to its 364-day multi-currency revolving secured credit facility effective April 22, 2026, maintaining the facility at $7 billion (expandable to $10 billion) for liquidity support in events like clearing firm defaults or payment disruptions. The facility is collateralized by clearing firm guaranty fund contributions and performance bond assets, with a consolidated tangible net worth compliance requirement. No changes to key terms beyond the amendment are disclosed.

• ·Filing submitted on April 27, 2026, reporting event of April 22, 2026.
• ·Exhibit 10.1: Amendment No. 11 to Credit Agreement filed.

27-04-2026

Profusa Inc. entered into an Asset Purchase Agreement dated April 21, 2026, with Bio Insights LLC to acquire substantially all know-how assets related to the PanOmics Platform, an integrated NGS multi-omics analysis platform for drug discovery and precision medicine, excluding patents and physical samples. In consideration, Profusa will issue Series A Convertible Preferred Stock to Bio Insights, convertible into common stock after one year subject to a 4.9% beneficial ownership limitation, with Seller granting a Sample Access License for up to [***] samples across two cohorts. The transaction follows due diligence and a non-binding Letter of Intent dated April 6, 2026, with no financial purchase price disclosed.

• ·No Patent Rights transferred; Seller retains all patents and rights to prosecute/maintain them.
• ·Sample Access License: Exclusive right to test up to [***] samples (Cohort 1: [***] samples deliverable within 30 Business Days post-Closing with [***] Consent Documentation; Cohort 2: [***] samples).
• ·Buyer assumes no liabilities of Seller.
• ·Shareholder Approval required for Nasdaq compliance (Rules 5635(a) and 5635(d)).

27-04-2026

Workhorse Group Inc. entered into Omnibus Amendment No. 1 with Motive GM Holdings II LLC, effective April 25, 2026, increasing the Cash Flow Credit Agreement commitment from $10,000,000 to $20,000,000 while reducing the Customer Order Credit Agreement commitment from $40,000,000 to $30,000,000. This doubles potential borrowing under the cash flow facility but cuts availability by 25% under the customer order facility. The amendment is subject to closing conditions including no default and reaffirmed representations and warranties.

• ·Interest on the $10,000,000 loan made on or about April 25, 2026, is due commencing after September 30, 2026.
• ·Amendment effective upon execution, no Event of Default, and reaffirmed representations and warranties.
• ·Governed by New York law; constitutes a Loan Document.

27-04-2026

AB Private Credit Investors Corp and multiple affiliated AB-Abbott private equity and credit funds entered into the Nineteenth Amendment to their Revolving Credit Agreement, originally dated June 14, 2019, with HSBC Bank USA, National Association as administrative agent and lenders, effective April 22, 2026. The amendment modifies certain sections and schedules of the Credit Agreement upon satisfaction of conditions including execution by parties, beneficial ownership certifications, and payment of fees to the agent and its counsel. No specific financial terms, changes in commitments, or performance metrics are disclosed in the filing.

• ·Amendment is the 19th since original Credit Agreement dated June 14, 2019
• ·Conditions precedent include executed counterparts, Beneficial Ownership Certifications, and payment of fees including to Cadwalader, Wickersham & Taft LLP
• ·Governed by laws of the State of New York

27-04-2026

InMed Pharmaceuticals Inc. (Nasdaq: INM) entered into amending agreements with Sabby Volatility Warrant Master Fund, Ltd. and affiliates of H.C. Wainwright & Co., LLC, reducing the exercise price of preferred investment options to $0.80 per common share (post-consolidation basis) from prior levels including $2.436 (Sabby) and up to $82.50 (Wainwright). These options allow Sabby to purchase up to 2,151,478 shares and Wainwright Parties up to 153,236 shares, though no assurance of exercise is provided. The amendments apply to options originally issued between November 2022 and June 2025.

• ·Original Sabby Preferred Investment Options dated October 26, 2023 and June 26, 2025.
• ·Original Wainwright Preferred Investment Options dated November 21, 2022, October 26, 2023 and June 26, 2025.
• ·Options offered in private placements under Section 4(a)(2) of Securities Act of 1933 and Regulation D.
• ·All share figures on post-consolidation basis.

27-04-2026

Gulf Resources, Inc. received a Nasdaq notice on April 23, 2026, stating non-compliance with Listing Rule 5250(c)(1) due to failure to timely file its Form 10-K for the year ended December 31, 2025. The notice has no immediate effect on the listing or trading of GURE common stock on Nasdaq Capital Market, but requires a compliance plan within 60 days, with potential extension to October 12, 2026, if accepted. The Company stated it is working diligently to complete the overdue filing amid risks of further delisting proceedings.

• ·Nasdaq may grant up to 180 calendar days from the Form 10-K due date if compliance plan is accepted.
• ·Company operates bromine and crude salt production in China through wholly-owned subsidiaries.
• ·Common stock: $0.0005 par value, traded as GURE on Nasdaq.

27-04-2026

Trio-Tech International announced the pricing of a $10 million registered direct offering of 1,052,632 shares of common stock to institutional investors, with closing expected on or about April 27, 2026. Gross proceeds, before fees and expenses, will fund working capital, general corporate purposes, and strategic investments to expand capacity in AI and automotive markets. D. Boral Capital LLC serves as the exclusive placement agent.

• ·Shelf Registration Statement on Form S-3 (File No. 333-291219) declared effective by SEC on December 16, 2025.
• ·Company operates in United States, Singapore, Malaysia, Thailand, and China.
• ·Annual Report on Form 10-K filed with SEC on September 19, 2025.

27-04-2026

Yesway, Inc. adopted and filed an Amended and Restated Certificate of Incorporation effective upon filing on April 27, 2026, restating and amending the original certificate from April 23, 2021. The amendment authorizes 660,000,000 total shares consisting of 500,000,000 Class A Common Stock, 150,000,000 Class B Common Stock, and 10,000,000 Preferred Stock, each with a par value of $0.0001 per share, and recapitalizes all existing common stock (par $0.001) into one share of Class A Common Stock. Class B shares are issuable only to permitted owners tied to Common Units in BW Ultimate Parent, LLC, with equal voting rights to Class A but no dividends except in specific cases.

• ·Recapitalization occurs automatically without further action, converting all Existing Common Stock (par $0.001) into one Class A Common share.
• ·Class A and Class B Common Stock vote together as a single class with one vote per share each.
• ·No dividends on Class B Common Stock except in connection with a poison pill or required stock adjustments.
• ·Class B shares restricted to Existing Owners, successors, assigns, and Permitted Transferees linked to Common Units under the LLC Agreement.

27-04-2026

Wheels Up Experience Inc. filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, effective immediately after NYSE close on April 24, 2026, reducing authorized capital stock to 100,000,000 shares (75,000,000 Class A Common Stock and 25,000,000 Preferred Stock, par value $0.0001 per share) and implementing a 1-for-20 reverse stock split on Class A Common Stock. No fractional shares will be issued; stockholders receive cash in lieu based on the adjusted NYSE closing price. The amendment was executed by Matthew J. Knopf, Chief Legal Officer & Secretary.

• ·Amendment replaces Section 4.1 in its entirety and was adopted pursuant to Section 242 of the Delaware General Corporation Law.
• ·Original Amended and Restated Certificate of Incorporation filed with Delaware Secretary of State on November 15, 2023.
• ·Cash payment for fractional shares calculated as adjusted NYSE closing price on April 24, 2026, multiplied by the fractional share amount.

27-04-2026

Velo3D, Inc. announced the pricing of a firm commitment underwritten registered direct offering of 3,571,428 shares of common stock at $14.00 per share, for gross proceeds of approximately $50 million before expenses. The offering, managed by Cantor Fitzgerald & Co. as sole book-running manager, is expected to close on or about April 28, 2026, subject to customary conditions, with net proceeds for working capital and general corporate purposes. No declines or underperformance noted in the announcement.

• ·Offering pursuant to effective S-3 shelf registration (File No. 333-294876), filed April 3, 2026 and effective April 8, 2026.
• ·Prospectus supplement to be filed with SEC.

27-04-2026

DMC Global Inc. entered into Amendment No. 2 to its Stockholder Protection Rights Agreement on April 24, 2026, extending the Expiration Time of the Rights from June 4, 2026, to June 4, 2027, with no other changes to the agreement. The Rights continue to restrict any person or group from acquiring beneficial ownership of 10% (or 20% for Passive Investors) or more of the outstanding common stock. This amendment modifies the rights of security holders but does not impact financial performance metrics.

• ·Original Rights Agreement dated June 5, 2024
• ·Amendment No. 1 dated May 30, 2025
• ·Rights Agent: Computershare Trust Company, N.A.
• ·Securities traded on The Nasdaq Global Select Market

27-04-2026

Ligand Pharmaceuticals (LGND) to acquire XOMA Royalty Corporation (XOMA) for $39.00 per share in cash, totaling approximately $739 million equity value (14% premium to 30-day VWAP), plus one CVR per share for 75% of net proceeds from Janssen litigation. The deal adds over 120 assets including seven commercial products, expected to close Q3 2026 and be immediately accretive to Ligand's adjusted EPS; Ligand raised 2026 guidance to revenue $270-310M (from $245-285M), royalties $225-250M (from $200-225M), and adjusted EPS $8.50-9.50 (from $8.00-9.00), with Captisol ($35-40M) and contract revenue ($10-20M) unchanged. Supported by BVF Partners (21% owner) and management voting agreements.

• ·Transaction funded by Ligand cash and credit facility; Series X Preferred converts to common, Series A/B redeemed prior to close.
• ·Investor call held April 27, 2026 at 8:00 a.m. ET.
• ·XOMA Series X Convertible Preferred Stock to convert at fixed price prior to closing.

27-04-2026

National Healthcare Properties, Inc. closed a registered public offering of 38,500,000 shares of Class A common stock on April 23, 2026, following an Underwriting Agreement dated April 21, 2026, with representatives Wells Fargo Securities, LLC, Morgan Stanley & Co. LLC, and BMO Capital Markets Corp. The underwriters exercised their option on April 24, 2026, to purchase an additional 5,775,000 shares to cover overallotments, with closing expected on April 28, 2026. No financial proceeds or performance metrics were disclosed in the filing.

• ·Registration statement on Form S-11 (File No. 333-294895)
• ·Underwriting Agreement filed as Exhibit 1.1
• ·Securities traded on The Nasdaq Global Market under symbols NHP, NHPAP, NHPBP

27-04-2026

Jaguar Health, Inc. (JAGX) announced via 8-K the Eleventh Amendment to its Third Amended and Restated Certificate of Incorporation, authorizing a seventh reverse stock split with a ratio between 15:1 and 150:1, to be finalized and announced by the Board prior to effectiveness. This action addresses Nasdaq delisting risks under Items 3.01 and 3.03 for failure to satisfy listing rules. The amendment takes effect at 12:01 a.m. ET on April 30, 2026, with fractional shares cashed out at the closing price on that date.

• ·Amendment authorized by Board of Directors and stockholders per Delaware General Corporation Law Section 242.
• ·Original Certificate of Incorporation filed June 6, 2013, as Jaguar Animal Health, Inc.
• ·Certificate signed April 24, 2026.

27-04-2026

Ligand Pharmaceuticals (LGND) announced a definitive agreement to acquire XOMA Royalty Corporation (XOMA) for $39 per share in cash, totaling approximately $739 million equity value, at a 14% premium to XOMA's 30-day VWAP, expanding Ligand's royalty portfolio to over 200 assets including seven new commercial products and nearly doubling Phase 2/3 assets. The deal is expected to close in Q3 2026, be immediately accretive to adjusted EPS, and drive $1.50 per share accretion in 2027. Ligand raised 2026 guidance to revenue of $270-310 million (previously $245-285 million), adjusted EPS of $8.50-9.50 (previously $8.00-9.00), and royalties of $225-250 million (previously $200-225 million), with no changes to Captisol or contract revenue guidance.

• ·Transaction funded by Ligand’s existing cash and credit facility borrowings.
• ·XOMA Royalty stockholders receive one non-transferable CVR per share for 75% of net proceeds from Janssen litigation.
• ·Expected close in Q3 2026, subject to XOMA stockholder approval and regulatory approvals.
• ·BVF Partners (21% common, 44% assuming Series X conversion) and XOMA directors/officers entered voting agreements.
• ·Investor conference call held April 27, 2026 at 8:00 a.m. ET.

27-04-2026

Golub Capital Private Credit Fund entered into the Fifth Amendment to its Senior Secured Revolving Credit Agreement dated September 6, 2023, effective April 23, 2026, which amends the agreement, adds New Lenders, and reduces commitments for certain Reducing Dollar Lenders. The amendment is supported by representations of no defaults or events of default and maintains all other terms in full force. No specific financial metrics or changes in borrowing capacity were disclosed in the filing.

• ·Previous amendments: First on May 6, 2024; Second on July 24, 2024; Third on November 22, 2024; Fourth on June 26, 2025.
• ·Conditions to effectiveness include signed counterparts, legal opinion, organizational documents, and payment of fees.
• ·Involves reallocation of existing Revolving Loans via prepayment and redrawing to reflect new commitments.